Kucera Lukas, Chudý Martin, Danková Marcela, Goncalvesová Eva
Department of Heart Failure and Heart Transplantation, Faculty of Medicine, Comenius University, Bratislava, SVK.
Cureus. 2025 Jul 9;17(7):e87586. doi: 10.7759/cureus.87586. eCollection 2025 Jul.
Background Dilated cardiomyopathy (DCM) is a leading cause of heart failure (HF). We retrospectively analyzed long-term survival in DCM and the impact of clinical factors on their prognosis. Methods This was a retrospective analysis of 622 DCM patients (484 men, 138 women). Survival was compared between the 2016-2019 and 2020-2023 cohorts. Results The mean age was similar between cohorts (54 ± 13 vs. 55 ± 13 years). Mean overall survival for the entire cohort was 84.1 ± 1.6 months (95% CI: 81.0-87.4). When analyzed by period, mean survival was 84.1 ± 2.0 months (95% CI: 80.3-87.9) for patients diagnosed between 2016 and 2019 and 53.4 ± 1.1 months (95% CI: 51.2-55.6) for those diagnosed between 2020 and 2023. The difference was not statistically significant (log-rank p = 0.856). The shorter mean survival in the later period reflects the limited follow-up time due to ongoing observation. In the 2020-2023 group, a higher proportion of patients were classified as New York Heart Association (NYHA) III/IV (56% vs. 48%, p = 0.036) and had larger ventricular diameters (left ventricular end-diastolic diameter (LVEDD): 68 ± 8 mm vs. 66 ± 7 mm, p = 0.001; right ventricle (RV): 36 ± 7 mm vs. 34 ± 6 mm, p = 0.001). Treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) did not significantly affect survival. Multivariable analysis identified older age, NYHA class III/IV, chronic kidney disease (CKD) stages 3-5, diabetes, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >3000 ng/L as independent negative predictors, while female sex and overweight status were associated with better survival. Multivariable analysis identified older age, NYHA III/IV, CKD stages 3-5, diabetes, and NT-proBNP >3000 ng/L as independent negative predictors. Female sex and overweight status were associated with improved survival. Conclusions Survival in DCM patients remained stable across time periods, despite a higher-risk profile in recent years, potentially influenced by the COVID-19 pandemic.
背景 扩张型心肌病(DCM)是心力衰竭(HF)的主要病因。我们回顾性分析了DCM患者的长期生存率以及临床因素对其预后的影响。方法 这是一项对622例DCM患者(484例男性,138例女性)的回顾性分析。比较了2016 - 2019年队列和2020 - 2023年队列的生存率。结果 各队列的平均年龄相似(54±13岁 vs. 55±13岁)。整个队列的平均总生存期为84.1±1.6个月(95%置信区间:81.0 - 87.4)。按时间段分析时,2016年至2019年诊断的患者平均生存期为84.1±2.0个月(95%置信区间:80.3 - 87.9),2020年至2023年诊断的患者为53.4±1.1个月(95%置信区间:51.2 - 55.6)。差异无统计学意义(对数秩检验p = 0.856)。后期平均生存期较短反映了由于持续观察导致的随访时间有限。在2020 - 2023组中,更高比例的患者被归类为纽约心脏协会(NYHA)III/IV级(56% vs. 48%,p = 0.036),且心室直径更大(左心室舒张末期内径(LVEDD):68±8 mm vs. 66±7 mm,p = 0.001;右心室(RV):36±7 mm vs. 34±6 mm,p = 0.001)。钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)治疗对生存率无显著影响。多变量分析确定年龄较大、NYHA III/IV级、慢性肾脏病(CKD)3 - 5期、糖尿病以及N末端B型利钠肽原(NT-proBNP)>3000 ng/L为独立的负性预测因素,而女性性别和超重状态与更好的生存率相关。多变量分析确定年龄较大、NYHA III/IV级、CKD 3 - 5期、糖尿病以及NT-proBNP>3000 ng/L为独立的负性预测因素。女性性别和超重状态与生存率改善相关。结论 尽管近年来风险状况较高,可能受新冠疫情影响,但DCM患者的生存率在不同时间段保持稳定。